Weak evidence on nalmefene creates dilemmas for clinicians and poses questions for regulators and researchers
Zapisane w:
Fitzgerald, N., et al., Weak evidence on nalmefene creates dilemmas for clinicians and poses questions for regulators and researchers. Addiction, vol. 111, n. 8, 2016, p. 1477-1487.
Ref.
514304
Lokalizacja:
SIIS Archivo (R.696) / SIIS R.696
Palabras clave:
Drogodependencias, Alcoholismo, Tratamiento médico, Fármacos, Efectos, Resultados, Evaluación de servicios, Literatura científica
Drogodependencias, Alcoholismo, Tratamiento médico, Fármacos, Efectos, Resultados, Evaluación de servicios, Literatura científica
Podobne zapisy: Weak evidence on nalmefene creates dilemmas for clinicians and poses questions for regulators and researchers
- Clinical relevance of as-needed treatment with Nalmefene in alcohol-dependent patients
- Risks and benefits of nalmefene in the treatment of adult alcohol dependence: a systematic literature review and meta-analysis of published and unpublished double-blind randomized controlled trials
- Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta‐analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate
- MEDICATION TREATMENT STRATEGIES IN THE MTA STUDY: RELEVANCE TO CLINICIANS AND RESEARCHERS
- ASSESSING ALCOHOL PROBLEMS. A GUIDE FOR CLINICIANS AND RESEARCHERS
- DILEMMAS OF THE MENTAL RETARDATION CLINICIAN. ANA SSIGNMENT FOR THE RESEARCHER. EN: PREVENTIVE AND CURATIVE INTERVENTION IN MENTALRETARDATIdi